For those subjects suffering from pancreatic cancer and bearing a CDKN2A mutation, the guidelines issued by the American Cancer of the Pancreas Screening Consortium [50] and the American College of Gastroenterology [51] are still the most up-to-date resources. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.